메뉴 건너뛰기




Volumn 103, Issue 10, 2012, Pages 1898-1904

Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

EID: 84867230515     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02382.x     Document Type: Article
Times cited : (21)

References (37)
  • 2
    • 0030940076 scopus 로고    scopus 로고
    • Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor
    • Endlhard M, Brittinger G, Huhn D et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997; 89: 2291-7.
    • (1997) Blood , vol.89 , pp. 2291-2297
    • Endlhard, M.1    Brittinger, G.2    Huhn, D.3
  • 3
    • 27244437953 scopus 로고    scopus 로고
    • Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas
    • De Paepe P, Achten R, Verhoef G et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23: 7060-8.
    • (2005) J Clin Oncol , vol.23 , pp. 7060-7068
    • De Paepe, P.1    Achten, R.2    Verhoef, G.3
  • 4
    • 0036498922 scopus 로고    scopus 로고
    • T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity
    • Achten R, Verhoef G, Vanuytsel L, Wolf-Peeters C. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002; 20: 1269-77.
    • (2002) J Clin Oncol , vol.20 , pp. 1269-1277
    • Achten, R.1    Verhoef, G.2    Vanuytsel, L.3    Wolf-Peeters, C.4
  • 5
    • 34547947640 scopus 로고    scopus 로고
    • The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
    • Park S, Lee J, Ko YH et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972-8.
    • (2007) Blood , vol.110 , pp. 972-978
    • Park, S.1    Lee, J.2    Ko, Y.H.3
  • 6
    • 24044473086 scopus 로고    scopus 로고
    • Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
    • Berglund M, Thunberg U, Amini RM et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113-20.
    • (2005) Mod Pathol , vol.18 , pp. 1113-1120
    • Berglund, M.1    Thunberg, U.2    Amini, R.M.3
  • 7
    • 0037217921 scopus 로고    scopus 로고
    • Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
    • Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
    • (2003) Blood , vol.101 , pp. 78-84
    • Colomo, L.1    Lopez-Guillermo, A.2    Perales, M.3
  • 8
    • 0030985194 scopus 로고    scopus 로고
    • Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
    • Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-51.
    • (1997) Blood , vol.90 , pp. 244-251
    • Gascoyne, R.D.1    Adomat, S.A.2    Krajewski, S.3
  • 9
    • 0030029443 scopus 로고    scopus 로고
    • Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groups d'Etude des Lymphomes de l'Adulte (GELA)
    • Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groups d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-72.
    • (1996) Blood , vol.87 , pp. 265-272
    • Hermine, O.1    Haioun, C.2    Lepage, E.3
  • 10
    • 0036464704 scopus 로고    scopus 로고
    • De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
    • Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-21.
    • (2002) Blood , vol.99 , pp. 815-821
    • Yamaguchi, M.1    Seto, M.2    Okamoto, M.3
  • 11
    • 0035883063 scopus 로고    scopus 로고
    • Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
    • Lossos IS, Jones CD, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945-51.
    • (2001) Blood , vol.98 , pp. 945-951
    • Lossos, I.S.1    Jones, C.D.2    Warnke, R.3
  • 12
    • 0028326055 scopus 로고
    • Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial
    • Miller TP, Grogan TM, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.
    • (1994) Blood , vol.83 , pp. 1460-1466
    • Miller, T.P.1    Grogan, T.M.2    Dahlberg, S.3
  • 13
    • 78049515807 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    • Younes A, Barlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-21.
    • (2010) N Engl J Med , vol.363 , pp. 1812-1821
    • Younes, A.1    Barlett, N.L.2    Leonard, J.P.3
  • 14
    • 33744960411 scopus 로고    scopus 로고
    • A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
    • Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-30.
    • (2006) N Engl J Med , vol.354 , pp. 2419-2430
    • Hummel, M.1    Bentink, S.2    Berger, H.3
  • 15
    • 77953030981 scopus 로고    scopus 로고
    • Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation
    • Ruzinova MB, Caron T, Rodig SJ. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol 2010; 34: 882-91.
    • (2010) Am J Surg Pathol , vol.34 , pp. 882-891
    • Ruzinova, M.B.1    Caron, T.2    Rodig, S.J.3
  • 16
    • 0034598746 scopus 로고    scopus 로고
    • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    • Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
    • (2000) Nature , vol.403 , pp. 503-511
    • Alizadeh, A.A.1    Eisen, M.B.2    Davis, R.E.3
  • 17
    • 0037142053 scopus 로고    scopus 로고
    • The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma
    • Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
    • (2002) N Engl J Med , vol.346 , pp. 1937-1947
    • Rosenwald, A.1    Wright, G.2    Chan, W.C.3
  • 18
    • 9144237554 scopus 로고    scopus 로고
    • Conformation of molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    • Hans SP, Weisenburger DD, Greiner TC et al. Conformation of molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
    • (2004) Blood , vol.103 , pp. 275-282
    • Hans, S.P.1    Weisenburger, D.D.2    Greiner, T.C.3
  • 19
    • 34249673388 scopus 로고    scopus 로고
    • Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
    • Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-5.
    • (2007) Blood , vol.109 , pp. 4930-4935
    • Nyman, H.1    Adde, M.2    Karjalainen-Lindsberg, M.L.3
  • 20
    • 0031927984 scopus 로고    scopus 로고
    • New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
    • Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
    • (1998) J Clin Oncol , vol.16 , pp. 2780-2795
    • Armitage, J.O.1    Weisenburger, D.D.2
  • 21
    • 33847361987 scopus 로고    scopus 로고
    • The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    • Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.
    • (2007) Blood , vol.109 , pp. 1857-1861
    • Sehn, L.H.1    Berry, B.2    Chhanabhai, M.3
  • 22
    • 78751580704 scopus 로고    scopus 로고
    • Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
    • Maruyama D, Watanabe T, Maeshima AM et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 2010; 92: 732-43.
    • (2010) Int J Hematol , vol.92 , pp. 732-743
    • Maruyama, D.1    Watanabe, T.2    Maeshima, A.M.3
  • 23
    • 82255186682 scopus 로고    scopus 로고
    • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
    • Récher C, Coiffier B, Haioun C et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-67.
    • (2011) Lancet , vol.378 , pp. 1858-1867
    • Récher, C.1    Coiffier, B.2    Haioun, C.3
  • 24
    • 0025255538 scopus 로고
    • Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines
    • Nunez G, London L, Hockenbery D et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602-10.
    • (1990) J Immunol , vol.144 , pp. 3602-3610
    • Nunez, G.1    London, L.2    Hockenbery, D.3
  • 25
    • 0006643029 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma
    • Knowles DM, ed., 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins
    • Anagnostopoulos I, Dallenbach F, Stein H. Diffuse large B-cell lymphoma. In: Knowles DM, ed. Neoplastic Hematopathology, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001; 855-913.
    • (2001) Neoplastic Hematopathology , pp. 855-913
    • Anagnostopoulos, I.1    Dallenbach, F.2    Stein, H.3
  • 26
    • 0030800097 scopus 로고    scopus 로고
    • Bcl-6 protein expression in normal and neoplastic lymphoid tissues
    • Falini B, Fizzotti M, Pileri S et al. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997; 8: 101-4.
    • (1997) Ann Oncol , vol.8 , pp. 101-104
    • Falini, B.1    Fizzotti, M.2    Pileri, S.3
  • 27
    • 0031766507 scopus 로고    scopus 로고
    • Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma
    • Chaganti SR, Chen W, Parsa N et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosom Cancer 1998; 23: 323-7.
    • (1998) Genes Chromosom Cancer , vol.23 , pp. 323-327
    • Chaganti, S.R.1    Chen, W.2    Parsa, N.3
  • 28
    • 0029562068 scopus 로고
    • Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma
    • Ye BH, Chaganti S, Chang CC et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995; 14: 6209-17.
    • (1995) EMBO J , vol.14 , pp. 6209-6217
    • Ye, B.H.1    Chaganti, S.2    Chang, C.C.3
  • 29
    • 0028227464 scopus 로고
    • Rearrangement of the Bcl-6 gene as a prognostic marker in diffuse large B-cell lymphoma
    • Offit K, Lo Coco F, Louie DC et al. Rearrangement of the Bcl-6 gene as a prognostic marker in diffuse large B-cell lymphoma. N Engl J Med 1994; 331: 74-80.
    • (1994) N Engl J Med , vol.331 , pp. 74-80
    • Offit, K.1    Lo Coco, F.2    Louie, D.C.3
  • 30
    • 0029898268 scopus 로고    scopus 로고
    • Bcl-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas
    • Pittaluga S, Ayoubi TA, Wlodarska I et al. Bcl-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas. J Pathol 1996; 179: 145-50.
    • (1996) J Pathol , vol.179 , pp. 145-150
    • Pittaluga, S.1    Ayoubi, T.A.2    Wlodarska, I.3
  • 31
    • 0032808894 scopus 로고    scopus 로고
    • Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities
    • Skinnider BF, Horsman DE, Dupuis B et al. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30: 803-8.
    • (1999) Hum Pathol , vol.30 , pp. 803-808
    • Skinnider, B.F.1    Horsman, D.E.2    Dupuis, B.3
  • 32
    • 34249821912 scopus 로고    scopus 로고
    • Rituximab therapy in malignant lymphoma
    • Coiffer B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-13.
    • (2007) Oncogene , vol.26 , pp. 3603-3613
    • Coiffer, B.1
  • 33
    • 0037698992 scopus 로고    scopus 로고
    • Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    • Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-84.
    • (2003) Blood , vol.101 , pp. 4279-4284
    • Mounier, N.1    Briere, J.2    Gisselbrecht, C.3
  • 34
    • 33744465008 scopus 로고    scopus 로고
    • Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma
    • Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 2006; 91: 715-6.
    • (2006) Haematologica , vol.91 , pp. 715-716
    • Mounier, N.1    Briere, J.2    Gisselbrecht, C.3    Reyes, F.4    Gaulard, P.5    Coiffier, B.6
  • 35
    • 33645791771 scopus 로고    scopus 로고
    • Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
    • Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207-13.
    • (2006) Blood , vol.107 , pp. 4207-4213
    • Winter, J.N.1    Weller, E.A.2    Horning, S.J.3
  • 36
    • 0032841028 scopus 로고    scopus 로고
    • Interferon regulatory factors: the next generation
    • Mamane Y, Heylbroeck C, Genin P et al. Interferon regulatory factors: the next generation. Gene 1999; 237: 1-14.
    • (1999) Gene , vol.237 , pp. 1-14
    • Mamane, Y.1    Heylbroeck, C.2    Genin, P.3
  • 37
    • 79959721309 scopus 로고    scopus 로고
    • CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab
    • Miyazaki K, Yamaguchi M, Suzuki R et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601-7.
    • (2011) Ann Oncol , vol.22 , pp. 1601-1607
    • Miyazaki, K.1    Yamaguchi, M.2    Suzuki, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.